Asymmetric dimethylarginine (ADMA):: A novel risk marker in cardiovascular medicine and beyond
Asymmetric dimethylarginine (ADMA):: A novel risk marker in cardiovascular medicine and beyond
复制标题
DOI：
10.1080/07853890500472151
复制
发表时间：
2006-01-01
影响因子：
4.4
通讯作者：
Böger, RH
中科院分区：
文献类型：
--
作者：
Böger, RH
有大量证据表明，内皮细胞在维持血管张力和结构中起着至关重要的作用。一氧化氮（NO）是一种主要的内皮源性血管活性介质之一，它是健康血管内皮细胞中由氨基酸前体L-精氨酸形成的内源性信使分子。内皮功能障碍是由各种心血管危险因素、代谢性疾病和全身或局部炎症引起的。解释内皮功能障碍发生的一种机制是血液中不对称二甲基精氨酸（ADMA）水平升高，ADMA是一种L-精氨酸类似物，可抑制NO形成，从而损害血管功能。补充L-精氨酸已被证明可以恢复血管功能并改善与血管功能障碍相关的各种疾病的临床症状。
There is abundant evidence that the endothelium plays a crucial role in the maintenance of vascular tone and structure. One of the major endothelium-derived vasoactive mediators is nitric oxide (NO), an endogenous messenger molecule formed in healthy vascular enclothelium from the amino acid precursor L-arginine. Endothelial dysfunction is caused by various cardiovascular risk factors, metabolic diseases, and systemic or local inflammation. One mechanism that explains the occurrence of endothelial dysfunction is the presence of elevated blood levels of asymmetric dimethylarginine (ADMA) - an L-arginine analogue that inhibits NO formation and thereby can impair vascular function. Supplementation with L-arginine has been shown to restore vascular function and to improve the clinical symptoms of various diseases associated with vascular dysfunction.